Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $13.71

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.71.

A number of research analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Benchmark lifted their price target on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. Finally, TD Cowen restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th.

Humacyte Price Performance

NASDAQ HUMA opened at $4.58 on Monday. Humacyte has a 12 month low of $2.48 and a 12 month high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a market capitalization of $576.43 million, a PE ratio of -3.42 and a beta of 1.32. The company’s 50 day simple moving average is $4.62 and its 200 day simple moving average is $5.67.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Company insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brookstone Capital Management acquired a new stake in shares of Humacyte during the 4th quarter valued at $56,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Humacyte during the 3rd quarter valued at $75,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at $83,000. FORA Capital LLC acquired a new stake in shares of Humacyte during the 3rd quarter valued at $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.